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Abstract
Nef and Vpr are lentiviral accessory proteins that have been implicated in regulation of cellular gene expression. We noticed that Vpr
can potentiate Nef-induced activation of nuclear factor of activated T cells (NFAT)-dependent transcription. Unlike Nef, which stimulated
calcium signaling to activate NFAT, Vpr functioned farther downstream. Similar to the positive effects of Vpr on most of the transcriptional
test systems that we used, potentiation of NFAT-directed gene expression was relatively modest in magnitude (two- to threefold) and
depended on the cell cycle-arresting capacity of Vpr. By contrast, we found that Vpr could cause more than fivefold upregulation of cyclic
AMP response element (CRE)-directed transcription via a mechanism that did not require Vpr-induced G2/M arrest. This effect, however,
was only evident under suboptimal conditions known to lead to serine phosphorylation of the CRE binding factor (CREB) but not to
CREB-dependent gene expression. This suggested that Vpr may act by stabilizing interactions with CREB and its transcriptional cofactor
CREB binding protein (CBP). Indeed, this effect could be blocked by cotransfection of the adenoviral CBP inhibitor E1A. These results
provide additional evidence for cell cycle-independent regulation of gene expression by Vpr and implicate CREB as a potentially important
target for Vpr action in HIV-infected host cells.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
Regulation of transcription in the infected host cell is
important for optimal replication of human immunodefi-
ciency virus 1 (HIV-1). Expression of the integrated provi-
rus depends on cellular transcription factors that bind to the
HIV-1 long terminal repeat element (LTR). The activity of
these factors can be modulated by viral regulatory proteins,
such as Nef and Vpr. On the other hand, regulation of
cellular transcription factors by viral proteins may also
promote HIV-1 replication more indirectly via changes in
the expression of genes involved in cellular activation and
immune responses.
Nuclear factor of activated T cells, NFAT, is an impor-
tant transcription factor in regulation of gene expression in
T cells. Together with activator protein-1 (AP-1) it pro-
motes transcription of several cellular genes involved in T
cell activation, such as interleukin-2 (IL-2) (for reviews, see
Crabtree, 1999; Rao et al., 1997). Increased production of
IL-2 is a critical step in T cell activation and also serves to
stimulate the surrounding resting T cells in an autocrine
fashion. Since the activation of T cells strongly correlates
with the ability of HIV-1 to infect and replicate in these
cells (Nabel and Baltimore, 1987; Stevenson et al., 1990)
NFAT has a central role in regulating HIV-1 infection. In
addition, it has been reported that NFAT can also directly
bind to and activate HIV-1 LTR (Kinoshita et al., 1997).
Nef is a 25- to 34-kDa myristoylated accessory (i.e., not
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essential for the viral life cycle) protein produced by pri-
mate lentiviruses. Nef has been shown to have a major
influence on development of AIDS-like disease in SIV (sim-
ian immunodeficiency virus)-infected rhesus macaques
(Kestler et al., 1991). It has also been observed that some
individuals with long-term nonprogressive HIV-1 infection
are infected with viruses carrying defective nef genes (Dea-
con et al., 1995; Kirchhoff et al., 1995). The molecular
mechanisms of the pathogenic effect of Nef are not clear,
but Nef is known to interact with several proteins involved
in cellular signaling (reviewed in Renkema and Saksela,
2000). One recently described function of Nef is to activate
the calcium/calcineurin signaling pathway leading to NFAT
activation (Manninen et al., 2000) by interacting with the
inositol trisphospate receptor type-1 (Manninen and Sak-
sela, 2002).
Vpr is another accessory protein of HIV-1. This small
(14–15 kDa) viral protein is packaged into mature virions
(Cohen et al., 1990a; Paxton et al., 1993) and localizes
mainly in the nuclei of infected cells (Lu et al., 1993). Vpr
increases viral replication and is known to have several
functions during different stages of HIV replication cycle
(for reviews, see Bukrinsky and Adzhubei, 1999; Emerman,
1996; Re and Luban, 1997; Sherman and Greene, 2002).
Vpr has been reported to enhance the transport of the viral
genome into the host cell nucleus (Heinzinger et al., 1994)
by promoting the interaction of the viral preintegration
complex with the cellular nuclear import machinery (Popov
et al., 1998a, 1998b; Vodicka et al., 1998). This may con-
tribute to the active nuclear import of the viral genome that
allows HIV-1 to infect nondividing cells, such as macro-
phages (Fouchier and Malim, 1999; Sherman and Greene,
2002). Another extensively studied function of Vpr is to
prevent the proliferation of the infected cells by causing the
cell cycle to arrest in the G2 phase (He et al., 1995; Jowett
et al., 1995; Re et al., 1995; Rogel et al., 1995). G2 arrest by
Vpr has been associated with increased HIV-1 LTR-driven
gene expression as well as modulalation of host cell apo-
ptosis (He et al., 1995; Jowett et al., 1995; Re et al., 1995;
Zhu et al., 2001).
In addition to HIV-1 LTR, Vpr has been found to en-
hance transcription directed by other promoters (Cohen et
al., 1990b). The mechanism underlying the transcriptional
regulation by Vpr is unclear. It has been shown that viral
LTR-driven transcription is highest in the G2 phase of the
cell cycle (Felzien et al., 1998; Forget et al., 1998; Gum-
muluru and Emerman, 1999), suggesting that at least some
of the transcriptional effects of Vpr may be due to a pro-
ductive intracellular milieu created by the Vpr-induced G2
arrest. It has also been suggested that Vpr mediates these
transcriptional effects more directly by physically interact-
ing with cellular transcription factors, including TFIIB (Ag-
ostini et al., 1996), a protein that belongs to the basal
machinery of transcription, Spl(Wang et al., 1995), a pro-
moter-bound transcription factor, and p300 (Felzien et al.,
1998), which is a transcriptional coactivator that itself does
not bind DNA in a sequence-specific manner and instead is
involved in communication between different transcription
factors and the RNA polymerase complex as well as chro-
matin modeling (for a review see Goodman and Smolik,
2000). On the other hand, the ability of Vpr to regulate
transcription via p300/CBP also appears to be coupled to G2
arrest (Felzien et al., 1998). By contrast, potentiation of
nuclear hormone receptor-mediated transcription, which in-
volves binding of Vpr to p300/CBP and requires the steroid
receptor coactivator consensus motif LXXLL in Vpr, is
clearly independent of Vpr-induced G2 arrest (Kino et al.,
1999, 2002; Sherman et al., 2000).
Given the diverse effects of Vpr on gene expression, this
study was undertaken to examine if Vpr might cooperate
with Nef to upregulate NFAT-dependent gene expression.
We found that Vpr could indeed potentiate Nef-induced
activation of NFAT-directed transcription, but through a
mechanism different from that utilized by Nef. Like most
other effects of Vpr on transcription, this potentiation cor-
related with the ability of Vpr to cause G2 arrest. Interest-
ingly, when a panel of transcriptional study systems was
examined in phorbol ester-stimulated Jurkat T cells, the
action of Vpr on cyclic AMP response element (CRE)-
directed gene expression appeared exceptional. The magni-
tude of the positive effect of Vpr on CREB (CRE binding
protein)-dependent transcription was greater than that in the
other systems examined and did not depend on the G2-
arresting property of Vpr. Thus, modulation of CRE-depen-
dent host cell gene expression may be another mechanism
by which Vpr promotes HIV infection independently of its
effects on the cell cycle.
Results
To examine if Vpr could potentiate induction of NFAT-
dependent gene expression caused by Nef we transfected
Jurkat T cells with different combinations of expression
vectors for Nef and Vpr together with a luciferase reporter
gene construct containing three copies of the distal NFAT
response element from the regulatory region of the IL-2
gene (Northrop et al., 1993). Activation of NFAT target
genes, such as IL-2, depends on the cooperative action of
the calcium-regulated NFAT and the protein kinase C
(PKC)/mitogen-activated protein kinase (MAPK)-regulated
transcription factor AP-1. The effects of Nef and Vpr on
NFAT-dependent gene expression were therefore tested in
otherwise unstimulated cells as well as in cells stimulated
with the PKC agonist phorbol 12-myristate 13-acetate
(PMA) and the calcium ionophore ionomycin alone or in
combination (Figs. 1A and B).
In agreement with our previous results (Manninen et al.,
2000) transfection of Nef triggered an activation of calcium
signaling resulting in nuclear translocation of NFAT, evi-
denced by a substantial increase in NFAT-dependent re-
porter gene activity compared with cells in which the PKC/
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MAPK/AP-1 pathway was similarly activated by PMA but
lacking Nef expression (Fig. 1A). When Vpr was cotrans-
fected with Nef a further threefold increase in NFAT-de-
pendent transcription was observed. Although Vpr potenti-
ated the effect of Nef, it failed to promote significant NFAT-
dependent luciferase expression on its own, suggesting that
unlike that of Nef, the effect of Vpr was not mediated via
activation of calcium signaling.
To examine the mechanism by which Vpr cooperated
with Nef we compared the effect of Vpr on NFAT-depen-
dent transcription in cells in which the PKC/MAPK or
calcium signaling pathways had been differentially acti-
vated. As shown in Fig. 1B, Vpr failed to substitute for the
chemical activators of either of the two signaling pathways
required for efficient NFAT-dependent gene expression.
Instead Vpr caused a two- to threefold increase in reporter
gene activity under all conditions tested, including that in
cells in which PKC/MAPK and calcium signaling pathways
were both maximally induced by a combination of PMA
and ionomycin. Together these results indicated that Vpr
did not act on the signaling pathways leading to NFAT/
AP-1 activation, but instead exerted its positive effect far-
ther downstream, perhaps at the level of transcriptional
activation in the nucleus.
Vpr has been reported to positively influence transcrip-
tion driven by other enhancers/promoters, such as HIV-1
LTR (Cohen et al., 1990b; Kino et al., 1999; Sherman et al.,
2000). We were therefore interested to compare the effects
of Vpr on transcription driven by various natural and ex-
perimental promoters. In addition to the NFAT reporter
plasmid described above we transfected Jurkat cells with
luciferase constructs containing multimers of consensus
binding sites for NF-B, AP-1, or CREB or one copy of the
HIV-1 LTR or the serum response element (SRE) of the
c-fos gene. These reporter plasmids were transfected either
alone or together with an expression construct vector for
Vpr fused with an HA epitope tag in either its N-terminus
(HA-Vpr; the same construct called simply Vpr above) or
C-terminus (Vpr-HA). Both of these HA-tagged proteins
contain the wild-type Vpr polypeptide sequence and are
capable of interacting with the nuclear import machinery to
become localized in the nucleus (Di Marzio et al., 1995).
However, only HA-Vpr but not Vpr-HA causes the cells to
arrest in G2 (He et al., 1995; Di Marzio et al., 1995), a
property that has previously been reported to correlate with
the ability of Vpr to positively regulate gene expression
(Cohen et al., 1990b; Felzien et al., 1998; Forget et al.,
1998; Goh et al., 1998; Gummuluru and Emerman, 1999).
Expression of the reporter constructs transfected with or
without Vpr was induced by a PMA treatment (or PMA plus
ionomycin in the case of NFAT) and the resulting luciferase
activities were measured (Fig. 2). We found that enhance-
ment of NFAT-dependent gene expression shared the same
Fig. 2. Effects of differentially tagged Vpr proteins competent or deficient
in causing cell cycle arrest on gene expression dependent on different
transcription factors. Jurkat cells were transfected with the indicated lucif-
erase reporter constructs together with an empty control vector, HA-Vpr
(G2 arrest competent) or Vpr-HA (G2 arrest deficient) and stimulated for
4 h with PMA (or PMA plus ionomycin in the case of the NFAT-
responsive reporter). The relative luciferase activities in lysates from these
cells were measured and are expressed as in Fig. 1A.
Fig. 1. HIV-1 Vpr potentiates Nef-induced activation of NFAT-dependent
gene expression. (A) Jurkat T cells were transfected with an NFAT-
luciferase reporter construct together with Nef and/or Vpr or a control
expression vector as indicated and stimulated with PMA for 4 h. Luciferase
activities normalized for transfection efficiency are shown relative to the
value from control cells not expressing Nef or Vpr, which was set to 1.0.
Variations in data from three representative experiments are indicated by
standard error bars. (B) Jurkat cells transfected with an NFAT-luciferase
together with Vpr or a control expression vector were subjected to 4 h of
treatment with different stimuli as indicated. The relative luciferase activ-
ities in these lysates were measured and are expressed as in A.
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characteristics with the action of Vpr on most of the other
promoters tested: the magnitude of the Vpr effect was rel-
atively modest, and it was only observed using HA-Vpr but
not with the G2 arrest-deficient Vpr-HA. This suggested
that Vpr may regulate these different promoters via a com-
mon molecular mechanism, which is somehow related to
the cell cycle arrest caused by Vpr. Interestingly, the CREB-
dependent reporter gene construct was a notable exception
in this regard. The effect of Vpr on CREB-mediated tran-
scription was strong (up to 15-fold), and although HA-Vpr
was more potent than Vpr-HA in inducing this effect, it did
not require the G2-arresting capacity of Vpr.
Of note, however, when the effect of Vpr on CREB-
mediated gene expression was examined in differentially
stimulated cells we found that the features discussed above
that distinguished this effect from those of Vpr on other
transcription systems were evident only in PMA-stimulated
cells (Fig. 3A). By contrast, in unstimulated cells as well as
in cells in which CREB activity was fully stimulated via the
cAMP/PKA pathway using forskolin, a specific activator of
adenylate cyclase, no effect by Vpr-Ha and CRE-directed
reported gene expression could be observed.
Previous studies of the effect of Vpr on LTR-mediated
transcription have implicated the CBP/p300 family of tran-
scriptional coactivators in the enhancement of gene expres-
sion by Vpr (Felzien et al., 1998). To examine if the G2
arrest-independent positive effect of Vpr on CREB-medi-
ated transcription in PMA-stimulated Jurkat cells was also
mediated via CBP/p300, we cotransfected these cells with
an expression vector for E1A, an adenoviral inhibitor of
CBP/p300 function (Arany et al., 1995; Lundblad et al.,
1995). Expression of E1A efficiently inhibited forskolin-
induced CREB activation down to approximately 25% of
the control cells not expressing E1A, but had no inhibitory
(instead a modest increasing) effect on CRE-directed tran-
scription in unstimulated and PMA-stimulated cells (data
not shown). For clarity, CRE-driven luciferase expression in
cells that did not express Vpr were normalized to a value of
1.0, and the positive effects of Vpr in E1A-transfected and
in control cells were expressed related to this. As evident in
Fig. 3B, E1A effectively inhibited transcriptional potentia-
tion by Vpr in this system, indicating that similar to the
transcriptional effects by Vpr reported before (Felzien et al.,
1998), the G2 arrest-independent enhancement of CRE-
directed transcription by Vpr-HA also depended on CBP/
p300 activity.
Although the underlying molecular mechanisms remain
to be characterized these studies show that, similar to the
previously described effects of Vpr on nuclear hormone
receptor-mediated transcription (Kino et al., 1999, 2002;
Sherman et al., 2000), the ability of Vpr to positively reg-
ulate CRE-directed gene expression in a CBP/p300-depen-
dent manner does not require its capacity to cause G2 arrest
and identify CREB-mediated gene transcription as a partic-
ularly prominent target of Vpr in regulation of host cell gene
expression.
Discussion
In this study we found that Vpr could cooperate with Nef
in activation of NFAT-dependent gene expression and
might thereby potentiate the positive effect of Nef on HIV-1
replication. Unlike Nef, however, Vpr did not act by stim-
ulating signaling pathways leading to NFAT activation.
Instead, the positive effect of Vpr on NFAT-directed gene
expression took place downstream of these signaling cas-
cades and was related to Vpr-induced cell cycle arrest. This
is in agreement with previous reports on Vpr-mediated
enhancement in other transcriptional systems (Goh et al.,
1998; Kino et al., 1999, 2002; Roux et al., 2000; Sherman
et al., 2000) and resembled the results obtained in this study
Fig. 3. Enhancement of CRE-directed transcription by Vpr depends on the
pathway leading to CREB activation and requires CBP/p300. (A) Jurkat
cells were transfected with a CRE-luciferase reporter together with an
empty vector or Vpr-HA and stimulated for 4 h with PMA or forskolin or
left untreated. The relative luciferase activities in lysates from these cells
were measured and are expressed as in Fig. 1A. (B) Jurkat cells were
transfected with a CRE-luciferase reporter together with different combi-
nations of expression vectors for Vpr and/or E1A as indicated in the figure
and stimulated for 4 h with PMA. The relative luciferase activities in
lysates from these cells were measured and are expressed as in Fig. 1A,
except that the values from cells not expressing Vpr and either transfected
or not with E1A were independently normalized to 1.0 to facilitate com-
parison of the relative effects of Vpr in the absence or the presence of E1A.
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using a panel of heterologous reporter gene constructs. An
interesting exception among the transcriptional reporters
that we tested, however, was a construct that depended on
CREB activity for expression. Compared to the Vpr-in-
duced increase in NFAT-, AP-1-, NF-B-, SRE-, and HIV-1
LTR-dependent transcription, the effect of Vpr on gene
expression directed by CRE sites was stronger and was also
observed when using a previously characterized Vpr variant
(Vpr-HA) that is unable to cause cell cycle arrest (Di Mar-
zio et al., 1995). The Vpr variant competent for G2 arrest
(HA-Vpr), however, was two- to threefold more efficient
than Vpr-HA in stimulating CRE-directed gene expression,
suggesting that its potent effect involved G2 arrest-depen-
dent as well as -independent mechanisms.
Interestingly, the effect of Vpr on potentiation of nuclear
hormone receptor-driven transcription has also been re-
ported to be G2 arrest independent (Kino et al., 1999;
Sherman et al., 2000). While physical interactions of Vpr
with the p300/CBP transcriptional coactivators have been
best documented in that setting (Kino et al., 2002), p300/
CBP has also been implicated in Vpr-mediated enhance-
ment of transcription in other systems (Felzien et al., 1998).
Enhancement of HIV-1 LTR-mediated gene expression, a
function of Vpr that has been shown to depend on its G2
arrest-inducing capacity, also appears to involve p300/CBP
(Felzien et al., 1998). In agreement with these reports we
found that the positive effects on CRE-directed transcription
of Vpr-HA as well as HA-Vpr could be blocked by cotrans-
fection of E1A, a viral CBP/p300 inhibitor. Moreover, we
have also noticed that E1A can efficiently inhibit the G2/M
arrest-associated positive effect of Vpr on NFAT- and
HIV-1 LTR-mediated gene expression (A.L.L. and K.S.,
unpublished data). Thus, both the cell cycle-dependent and
-independent effects of Vpr on gene expression that we
observed seemed to depend on CBP/p300 function.
Stimulation of glucocorticoid receptor (GR)-mediated
transcription by Vpr has been shown to involve an interac-
tion of the C-terminal part of Vpr with CBP/p300 (Kino et
al., 2002) and of the LXXLL (amino acids 64–68) motif of
Vpr with GR (Kino et al., 1999). Considering that CBP was
originally identified and named as a transcriptional cofactor
of CREB (Chrivia et al., 1993), it will be interesting to
examine if the effect of Vpr on CRE-mediated transcription
involves direct stabilization of the interaction between
CREB and CBP/p300. In this regard it is intriguing to note
that Vpr-HA augmented CRE-mediated gene expression in
PMA-stimulated cells but not in cells in which the cAMP/
PKA pathway had been activated by forskolin. Previous
work by Montminy and colleagues has established phos-
phorylation of Ser133 in CREB as a key regulatory event in
CRE-mediated gene expression (Gonzalez and Montminy,
1989) and critical for recruitment of CBP/p300 in complex
with CREB (Arias et al., 1994; Chrivia et al., 1993). How-
ever, although stimulation of T cells via T cell receptor
(TCR) or with the phorbol ester PMA results in equally
efficient phosphorylation of CREB Ser133 as does activa-
tion of the cAMP/PKA pathway, only the latter stimulus is
sufficient to direct CREB-CBP/p300 complex formation
and increase in CRE-dependent gene expression (Brindle et
al., 1995; Mayr et al., 2001; Wagner et al., 2000). Thus, in
addition to Ser133 phosphorylation, a yet unidentified sig-
nal also involved in promoting CREB-CBP/p300 binding is
delivered in forskolin-stimulated cells but not in PMA-
stimulated cells. Our results suggest that Vpr expression
may either trigger this second signal or alternatively render
it unnecessary by directly stabilizing the complex formation
between CBP/p300 and Ser133-phosphorylated CREB. By
contrast, Vpr expression did not trigger activation of cellular
kinases capable of phosphorylating CREB at Ser133, ex-
plaining why the positive effect of CREB was observed
only in PMA-stimulated cells. On the other hand, Vpr-HA
did not have any positive effect on CREB activity in fors-
kolin-stimulated cells, presumably because this second sig-
nal was already provided by cAMP/PKA activation. These
results are in agreement with previous data by Kino et al.
(1999), who did not observe Vpr-induced potentiation of
CREB-mediated transcription in cells stimulated by over-
expression of a dominantly active form of PKA and there-
fore concluded that unlike GR function CREB activity
could not be enhanced by Vpr.
The present results implicate CREB as a potentially
important new target for Vpr action in HIV-infected host
cells. Our data suggest that a number of mitogenic and other
extracellular signals leading to CREB-S133 phosphoryla-
tion, but normally not to enhancement of CRE-mediated
transcription, might lead to abnormal upregulation of
CREB-dependent genes in Vpr-expressing cells. While the
majority of genes that contain consensus CRE sites in their
enhancers are involved in metabolic pathways, CREB also
participates in regulation of a number of genes involved in
immune functions, including IL-2 (Mayr and Montminy,
2001). Thus, in addition to the G2 arrest-associated poten-
tiation of the function of transcription factors such as NFAT
and NF-B, Vpr also has the capacity to promote HIV
replication by modulating T cell gene expression via CREB
binding sites in a CBP/p300-dependent but cell cycle-inde-
pendent manner.
Materials and methods
Plasmids
The eF1 promoter-driven vectors for expression of Nef
and -galactosidase (pLacZ) have been described in our
previous work (Manninen et al., 2001). The same paper also
describes the NFAT-luciferase construct with three tandem
short binding sites for NFAT (286 to257 of human IL-2
enhancer) in front of a minimal IL-2 promoter, the AP-1-
luciferase construct with five copies of the AP-1 binding site
from the metallothionein promoter also driving a minimal
IL-2 promoter, and the SRE-luciferase construct containing
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the serum response element (SRE) of the c-fos gene. The
NF-B-luciferase reporter (pBIIX) containing two Ig-de-
rived NF-B binding sites in front of a minimal murine fos
promoter (56 to109) has also been previously described
(Saksela and Baltimore, 1993). The CRE-luciferase (pCRE-
luc) construct is identical to pBIIX, except that two consen-
sus CREB binding sites (TGACGTCA) separated by four
nucleotides (GATC) were engineered into this plasmid to
drive the minimal fos promoter. The same plasmid back-
bone was also used to construct the HIV-1 LTR-luciferase
plasmid by inserting a PCR-generated Hind III–Bam HI
fragment containing the complete (except for the 10 most 5
nucleotides) U3 region and the TAR element of the R region
(1 to 68) from HIV-1HXB2 in place of the CRE sites and
the fos promoter. The CMV-driven vectors expressing dif-
ferentially HA epitope-tagged HIV-1NL4–3 Vpr proteins
were provided by Dr. N. Landau (The Salk Institute for
Biological Studies, La Jolla, CA, USA) and have been
described previously (Di Marzio et al., 1995).
Cells, transfections, and stimulations
Jurkat (JE-6 from ATCC) cells were maintained in RPMI
1640 medium (Hyclone) supplied with 2 mM glutamine
(Hyclone) and 10% fetal calf serum (BioWhittaker) without
antibiotics. Cultures were diluted 1 day prior to transfection
into about 0.4 million cells/ml and about 2 million cells
were used per transfection. Transfections were done with
DMRIE-C reagent (Gibco Life Technologies) according to
manufacturer’s instructions; 800 ng of the luciferase report-
ers, 300 ng of the LacZ reporter, and 1 g of the Nef and
Vpr expression vectors were included in each transfection
reaction. At 20–24 h after transfection cultures were stim-
ulated with 100 ng/ml of PMA (Sigma) and/or 1 l/ml of
calcium ionophore ionomycin (A23187, Calbiochem), with
50 ng/ml of anti-CD3 (HIT3a) antibody (Pharmingen), or
with 50 M forskolin (Sigma) for 4 h.
Luciferase assays
Harvested cells were washed once with 0.5 ml of PBS
and lysed in 200 l of 1  cell culture lysis buffer (Pro-
mega). Luciferase activities from the cell lysates (20 l)
were measured using Promega luciferase reagents. To de-
termine -galactosidase activities in the same lysates 100 l
of the lysates was mixed with 10 l of 10x LacZ buffer (500
mM NaCl, 100 mM MgCl2, 100 mM -mercaptoethanol)
and 100 l of 10 mM o-nitrophenyl -D-galactopyranoside
(Sigma). Reactions were incubated at 37°C until a yellow
color appeared and their absorbances were measured at 420
nm. The absorbance values were divided by the mean of all
-galactosidase values from the same experiment, and the
corresponding luciferase measurements were then normal-
ized for the transfection efficiency based on this ratio.
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